7th Annual China Healthcare Summit China Healthcare Summit *Please note: All events are in China Standard Time Schedule July 20, 2020 ACCESS TO BIOCENTURY BUSINESS INTELLIGENCE AND PRE-EVENT WEBINARS BEGINS September 17, 2020 **CHINA SUMMIT SCENE SETTER 1** Financing seven years of the "Bridge to Innovation": How much money is pouring into China's biotech ecosystem? September 28, 2020 1x1 MEETING SYSTEM LAUNCHES October 8, 2020 **CHINA SUMMIT SCENE SETTER 2** Matching money to innovation: What innovations are Chinese investors prioritizing? October 12, 2020 **CHINA SUMMIT SURVEY** partners. Survey results will be discussed during a special "Blue Ribbon" Panel, November 9.

As a member of the China Summit Community, please join us in predicting where the Bridge to Innovation is taking China innovators and their October 13, 2020 8:00 AM - 9:00 AM TODAY'S FUNDING ENVIRONMENT: WILL THE CHINA BREAKOUT CONTINUE? (Live Webinar)

2020 is already a breakout year for fundraising by Chinese biopharma companies, even after reaching new peaks in 2018 and 2019. A rush of domestic IPOs has lifted the boats of venture stage companies along with

David Flores, President & CEO, BioCentury Inc. (Session Chair)

James Huang, Founding Managing Partner, Panacea Venture

October 22, 2020

October 26, 2020

October 26, 2020

October 29, 2020

8:00 PM - 9:00 PM

November 5, 2020

medical team in Wuhan

November 5, 2020

November 9, 2020

November 9, 2020

9:00 AM - 9:30 AM

November 9, 2020

November 9, 2020

November 9, 2020

4:00 PM - 5:00 PM

November 9, 2020

8:00 PM - 9:00 PM

November 10, 2020

9:00 AM - 10:00 AM

November 10, 2020

10:30 AM - 11:30 AM

November 10, 2020

1:00 PM - 1:40 PM

November 10, 2020

3:00 PM - 3:40 PM

November 10, 2020

4:00 PM - 5:00 PM

November 11, 2020

November 11, 2020

November 11, 2020

2:00 PM - 3:00 PM

November 11, 2020

5:00 - 6:00 PM

November 11, 2020

7:00PM - 8:00PM

November 12, 2020

November 12, 2020

November 12, 2020

2:00 PM - 3:00 PM

November 12, 2020

5:00 PM - 6:00 PM

November 12, 2020

8:00 PM - 9:00 PM

November 13, 2020

November 13, 2020

8:00 AM - 9:00 AM

November 13, 2020

9:00 PM - 9:30 PM

1x1 Virtual Meetings + On-Demand Program

10:30 AM - 11:30 AM

9:00 AM - 10:00 AM

10:30 AM - 11:30 AM

9:00 AM - 10:00 AM

11:00 AM - 12:00 PM

9:30 AM - 10:30 AM

ROADSHOW TRACKS (Pre-Recorded)

Global Biotech Track, Hosted by Zai Lab Ltd.

CHINA SUMMIT SCENE SETTER 3

Drivers of China's Partnering Landscape

China-U.S. Case Study: I-Mab/AbbVie:

Jielun ZHU, CFO, I-Mab Biopharma

CHINA SUMMIT SCENE SETTER 4

CASE STUDY: CROSS-BORDER DEALS (Pre-Recorded Webinar)

Weimin TANG, Ph.D., EVP, Global Business Head, I-Mab Biopharma

MedTech Scene Setter: Trends in China MedTech Innovation.

BACK TO SCHOOL LESSONS FROM COVID (Pre-Recorded Webinar)

Zhi HONG, Ph.D., Co-Founder, President & CEO, Brii Biosciences Dan Zhang, M.D., Co-Founder, Director & CSO, ClinChoice Inc..

Nisa Leung, Managing Partner, Qiming Venture Partners

China Riotech (Next Wave) Track Hosted by ReiGene Ltd.

China Biotech (Public) Track, Hosted by BioCentury & BayHelix

What drug developers and policy makers in China need to learn from the pandemic.

Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc. (Session Chair)

FIRESIDE CHAT: CHINA'S RESPONSE TO COVID (Pre-Recorded Audio Interview)

Belgium Biotech Track, Hosted by AGIO Capital, Flanders Investment and Trade & AWEX

SCIENCES INDUSTRY (Pre-Recorded Webinar)

David Flores, President & CEO, BioCentury Inc.

Li CHEN, Ph.D., Founder & CEO, Hua Medicine Ltd.

Nisa Leung, Managing Partner, Qiming Venture Partners Antoine Papiernik, Managing Partner, Sofinnova Partners

road? Is there a choice between globally facing or inwardly facing?

Michael Yu, Ph.D., Co-Founder, Chairman & CEO, Innovent Biologics Inc.

FIRESIDE CHAT: CHINA'S INFRASTRUCTURE FOR INNOVATION (Pre-Recorded Webinar)

Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee) Lingshi TAN, Ph.D., Founder, Chairman & CEO, dMed Biopharmaceutical Co. Ltd. (Session Chair)

CHINA BIOTECH CASE STUDIES: NEXT-GENERATION INNOVATION (Pre-Recorded Webinar)

Case Studies with Chinese biotechs pursuing truly next-generation innovations.

Liang Schweizer, Ph.D., Co-Founder, President & CEO, HiFiBiO Therapeutics

Wendy Pan, Ph.D., Partner, Goodwin & Procter LLP (Session Chair)

Alan Jiang, M.D., Ph.D., Director & Chief Strategy Officer, XtalPi Inc. Guo-Liang YU, Ph.D., Co-Founder, Chairman & CEO, Apollomics Inc.

THE BRIDGE TO INNOVATION REPORT - BIOPHARMA (Live Webinar)

VIEW FROM THE TOP - BIOPHARMA CHINA GM PERSPECTIVES (Live Webinar)

Jin Wang, Partner & Co-Leader, China Healthcare Practice, McKinsey & Co. (Session Chair)

Cecilia Qi, VP, General Manager, Pharmaceuticals & Vaccines, China, GlaxoSmithKline

IP REFORM IN CHINA: WHAT INNOVATORS NEED TO KNOW (Pre-Recorded Webinar)

Tony Chen, J.D., Chairman, BayHelix, and Partner, Jones Day LLP (Session Chair)

edition), created exclusively for the China Healthcare Summit.

Fangning ZHANG, Partner, McKinsey & Co. (Session Co-Chair)

Siyuan CHEN, General Manager, China, Bristol Myers Squibb Co.

Michael Lai, M.D., General Manager, AstraZeneca China

Act impact China biotechs and Western innovators?

Dajun YANG, M.D., Ph.D., Chairman & CEO, Ascentage Pharma

CHINA BIOTECH FIRESIDE CHAT: BEIGENE (Pre-Recorded Webinar)

John Oyler, Founder, Chairman & CEO, BeiGene Ltd. (Session Chair) Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc. (Moderator)

Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc. (Session Chair)

Alex Kopitsas, Head, Human Resources, China, Johnson & Johnson

Joan Huaqiong Shen, M.D., Ph.D., CEO & Director, I-Mab Biopharma

edition), created exclusively for the China Healthcare Summit.

Florian Then, M.D., Partner, McKinsey & Co. (Session Chair) June Chang, President, Greater China, Boston Scientific Corp.

KOREA BIOTECH ROUNDTABLE (Pre-Recorded Webinar)

BG Rhee, Ph.D., CEO, SCM Life Sciences

stock China-focused pipelines?

CEO, AlchiMedics S.A.S.

Chair)

Lucien Goffart, CEO, Robocath Inc.

Jianhua SUN, Ph.D., Chairman & CEO, SINOMED

Roche

to discuss opportunities for collaboration with Korea biotechs.

Jeff Cranmer, Executive Editor, BioCentury Inc. (Session Chair) James Jungkue Lee, Founder & CEO, Bridge Biotherapeutics Inc. Sangwoo Lee, President, Korea Investment Partners US Inc.

BIOPHARMA CROSS-BORDER PARTNERING (Pre-Recorded Webinar)

Stella Xu, Ph.D., Managing Director, Quan Capital (Session Chair) Melissa Bradford-Klug, Chief Business Officer, Citrine Medicine

Guillaume Vignon, SVP, Business Development, BeiGene Ltd.

MEDTECH CROSS-BORDER PARTNERING (Pre-Recorded Webinar)

Olivier d'Arros, Partner, Mavie Technologies (Session Chair)

5TH ANNUAL HEADS OF R&D ROUNDTABLE (Live Webinar)

to discuss where China's biotech innovators go from here.

Kerry Blanchard, M.D., Ph.D., CEO, Everest Medicines Ltd.

Feng GUO, Ph.D., CEO, Genor Biopharma Co. Ltd.

Judith Li, Partner, Lilly Asia Ventures

the pros and cons of where to list.

Jielun ZHU, CFO, I-Mab Biopharma

Billy Cho, CFO, Zai Lab

technology to the fore.

James Lin, Partner, Davis Polk (Session Chair)

Ying Huang, Ph.D., CFO, Legend Biotech Corp. Shaojing TONG, CFO, InnoCare Pharma Ltd.

opportunities for cross-border collaboration.

Lifei CHENG, Ph.D., Founder & CEO, MedTecX

Reserved for 1x1 virtual meetings and watching on-demand recordings of China Summit sessions.

A post-election view from Washington.

Brad Loncar, CEO, Loncar Investments

George Baeder, Chief Strategy Officer, dMed Global David Beier, J.D., Managing Director, Bay City Capital

Anne Osdoit, Partner, MDStart Fund, Sofinnova Partners

Steve Yang, Ph.D., Co-CEO, WuXi AppTec Co. Ltd. (Session Chair)

Sharon Chan, DPhil, Head, JLABS@Shanghai, Johnson & Johnson

Hong SHEN, Ph.D., Site Head, Innovation Center Shanghai, Roche

What do HKEX and STAR investors expect from their big bets on IPOs?

Bin LI, Ph.D., Founder, CEO & Chief Investment Officer, Lake Bleu Capital

C-SUITE BOOTCAMP: HKEX/NASDAQ IPO STRATEGIES (Pre-Recorded Webinar)

U.K. BIOTECH SHOWCASE: NOVEL TECHNOLOGIES (Pre-Recorded Webinar)

Stephen Megit, Ph.D., Vice President of Business Development, Immunocore Ltd. Peter Wrighton-Smith, Ph.D., Founder & CEO, Oxford Immunotec Global plc

MEDTECH INNOVATION SPOTLIGHT: NOVEL TECHNOLOGIES (Pre-Recorded Webinar)

David Cassak, Co-Editor-in-Chief & Managing Partner, MedTech Strategist (Session Chair)

Hanson S. Gifford III, Co-Founder & Managing Partner, The Foundry LLC

CLOSING PLENARY: FIRESIDE CHAT FROM WASHINGTON (Live webina)

11TH ANNUAL BAYHELIX AWARDS CEREMONY (Pre-recorded Webinar)

Tony Chen, J.D., Chairman, BayHelix and Partner, Jones Day LLP (Emcee)

the Year; Person of the Year; and Woman Leader of the Year.

Dan Wang, M.D., Head, Johnson & Johnson Innovation, Asia Pacific

Steve Bates, CEO, BIA (U.K. BioIndustry Association) (Session Chair)

Jason C. Foster, CEO & Executive Director, Ori Biotech Ltd.

Ruth McKernan, Ph.D., Chairman, BIA & AstronauTX Ltd.

Shirley Lin, Managing Director, GL Capital Management GP Ltd. Steven Wang, Ph.D., Partner & Senior Managing Director, OrbiMed

CAPITAL MARKETS SHOWCASE: CAPITAL EFFICIENCY IN CHINA (Pre-Recorded Webinar)

Meng LI, SVP, Business Development & Strategy, Luoxin Pharmaceutical

Ning Ll, Ph.D., Executive Director, CEO & GM, Shanghai Junshi Biosciences Co. Ltd.

Bing Yuan, Ph.D., Chief Strategy & Business Officer, CStone Pharmaceuticals Co. Ltd.

licensing model or the equity model and what are the lessons learned for others.

Jonathan Chen, Chief International Business Officer, MicroPort Scientific Corp.

Jerry Wang, President, Greater China, Siemens Healthineers Ltd. Shirley Xu, President, Greater China, Baxter International Inc.

Kevin Wu, Ph.D., Associate Partner, McKinsey & Co. (Session Chair)

VIEW FROM THE TOP - MEDTECH CHINA GM PERSPECTIVES (Pre-Recorded Webinar)

market is headed and how they plan to address today's major uncertainties.

Nisa Leung, Managing Partner, Qiming Venture Partners

United States Patent and Trademark Office

Pius S. Hornstein, Ph.D., Country Chair & General Manager, Sanofi China

Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd.

Dianna Qian, Partner, Pivotal Bioventure China (Session Chair)

Eddy Wu, Ph.D., Founder, Director & CEO, Arctic Vision Ltd. Jinzi WU, Ph.D., Founder, Chairman & CEO, Ascletis Pharma Inc. Luhan YANG, Ph.D., Founder & CEO, Qihan Biotechnology Inc.

Tony Chen, J.D., Chairman, BayHelix, and Partner, Jones Day LLP

Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc. (Session Co-Chair)

Christian Hogg, Executive Director & CEO, Chi-Med (Hutchison China MediTech Ltd.)

Fangning ZHANG, Board Member, BayHelix, and Partner, McKinsey & Co. (Session Co-Chair)

Korea Biotech Track, Hosted by KHIDI (Korea Health Industry Development Institute)

this journey.

Webinar)

(Pre-Recorded Webinar)

Ophthalmology Ltd.

Association)

uncertainties.

High People's Court

should companies take?

Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc. (Moderator)

Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital (Session Chair) Niels Emmerich, Ph.D., VP, Global Head Search & Evaluation, AbbVie Inc.

Rahul Jerath, Senior Director, Business Development & Acquisitions, AbbVie Inc.

MEDTECH INNOVATION IN CHINA (Live Webinar)

Ray Yang, Partner, Marathon Venture Partners

Michael Zhao, CEO, DiNovA Medtech

Charlene Zhang, Ph.D., Founder & CEO, Neuroinvent

A closer look at the key drivers of MedTech innovation in China.

David Cassak, Co-Editor-in-Chief & Managing Partner, MedTech Strategist (Session Chair)

Wei CAO, M.D., Associate Professor, Department of Infectious Diseases, Peking Union Medical College Hospital (PUMCH), and member, PUMCH

WELCOMING REMARKS FROM BIOCENTURY & BAYHELIX: AN UNPRECEDENTED YEAR FOR THE LIFE

CHINA SUMMIT SURVEY RESULTS: WHERE IS THE "BRIDGE TO INNOVATION" HEADED? (Pre-Recorded

BioCentury and BayHelix unveil the results of the China Summit Survey and convene a panel of experts to discuss where the "Bridge to Innovation" is taking Chinese innovators and their international partners.

BLUE RIBBON PANEL: CHINA BIOTECH CEOs - A DISCUSSION WITH FIRST WAVE & NEXT WAVE INNOVATORS

First Wave CEOs and Next Wave CEOs meet to discuss the latest on China innovation. Do they see a fork in the

Is China's regulatory and commercial infrastructure ready to support the new flood of fast-moving biotechs?

Insights Partner McKinsey & Co. delivers the key findings from its 6th Bridge to Innovation report (biopharma

Biopharma businesses in China are at a new crossroads, with innovation taking off and mature brands under the pressure of volume-based purchasing policies. In the Summit's 7th annual GM plenary, China Country presidents share their views on where the market is headed and how they plan to address today's major

A new China Patent Law Amendment includes patent linkage for the first time. How will China's Hatch-Waxman

Yongshun CHENG, Director, Beijing Intellectual Property Institute, and former Senior Judge, IP Division, Beijing

David Kappos, J.D., Partner, Cravath, Swaine & Moore LLP, and former Under Secretary of Commerce & Director,

In a 1x1 discussion with BioCentury, BeiGene CEO John Oyler provides his take on where China innovators are

FIRESIDE CHAT ON DIVERSITY WITH BIO, BAYHELIX AND BIOCENTURY (Pre-Recorded Webinar)

Kathy He, Co-Chair, BayHelix Women's Initiative & Chief Business Officer, Kira Pharmaceuticals Ltd.

THE BRIDGE TO INNOVATION REPORT - CHINA MEDTECH: PATH TO A GLOBAL LEADING MARKET (Live

Insights Partner McKinsey & Co. delivers the key findings from its 6th Bridge to Innovation report (MedTech

In the Summit's inaugural MedTech GM plenary, China Country presidents share their views on where the

Stanley Su, CEO & Managing Director, Greater China, B.Braun Medical (Shanghai) Int'l Trading Co. Ltd.

BioCentury, BayHelix and KHIDI (Korea Health Industry Development Institute) bring together industry leaders

Will the rise of big Chinese biotechs mean even more demand - and competition - for international assets to

Urs Schleuniger, Ph.D., Global Head, Asset and Alliance Management & Interim Head, Roche Pharma Partnering,

Western MedTechs are increasingly looking to China for a trustworthy and reliable partner to help drive the next horizon of opportunities with growth and capital. What are the key strategies needed to find the right partner and how do you ensure long-term success? This panel explores two recent cross-border deals (MicroPort-Robocath; SinoMed-AlchiMedics) to understand why they chose the joint-venture model, the

Christophe Bureau, VP Strategic Innovation, SINOMED (Sino Medical Sciences Technology Inc.), and Founder &

The Summit's 5th annual Heads of Research Roundtable will bring together CSOs, CMOs and "scientist-CEOs"

Vijay Karwal, Managing Director & Head of Healthcare Investment Banking Asia (ex-Japan), Nomura (Session

Should you list on HKEX or NASDAQ? This session is especially tailored for Chinese executives who must weigh

BioCentury, BayHelix and BIA bring together U.K. biotech leaders to discuss advanced therapies and

As the Chinese MedTech market evolves, domestic companies will play a greater role in bringing truly

Steve Usdin, Senior Editor, Washington & Head of Policy and Regulation, BioCentury Inc. (Session Chair)

For the 11th year, BayHelix celebrates outstanding individuals and companies for achievements and

contributions to China's healthcare ecosystem: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; COVID-19 Social Responsibility Initiatives (Company; Person) of

innovative technology to the market. In this session, executives from four MedTech incubators - two Western, two Chinese - will talk about MedTech innovation and the opportunities and challenges in bringing truly novel

Michael Chan, Head, International Issuer Services, HKEX (Hong Kong Exchanges and Clearing Ltd.)

Cecelia Zhou, VP & General Manager, Trauson (China) Medical Instrument Co., Stryker Corp.

Michelle McMurry-Heath, M.D., President & CEO, BIO (Biotechnology Innovation Organization)

The life sciences industry this year has publicly committed itself to greater diversity. What specific measures

Gaobo ZHOU, Partner & Co-Leader, China Healthcare Practice, McKinsey & Co. (Session Co-Chair)

Ruilin SONG, Executive President, PhIRDA (China Pharmaceutical Innovation and Research Development

Benjamin Li, Ph.D., Founder & CEO, Lee's Pharmaceutical Holdings Ltd., and Chairman & CEO, Zhaoke

It has been an unprecedented year for global health and for the life sciences industry. Please join BioCentury and BayHelix for this special Welcome Session to discuss our first digital event and the 7th China Healthcare Summit. Now more than ever it is important to connect and learn from each other. We hope you will join us on

A landmark deal reveals current cross-border dynamics.

Bihua Chen, CEO & Portfolio Manager, Cormorant Asset Management

Bin LI, Ph.D., Founder, CEO & Chief Investment Officer, Lake Bleu Capital

bankers discuss today's funding dynamics and discuss how long the pace can continue.

Vijay Karwal, Managing Director & Head of Healthcare Investment Banking Asia (ex-Japan), Nomura

the fortunes of Chinese investment banks. In this pre-conference webinar, seasoned Chinese investors and bio-